Blood-Based Cancers Diagnostic and Treatment Services
Patients with hematologic malignancies often have a complex array of medical issues. Our Hematologic Malignancies Service brings together a team of specialists to provide patients with individualized treatment plans without duplicating services. Patients are evaluated by:
- Medical oncologists/hematologists
- Specialized nurses, nurse practitioners, and research nurses
- Radiation oncologists
- Pathologists
- Nutritionists
- Social workers
The team offers a comprehensive range of diagnostic and treatment services designed to provide patients with the most effective care possible. Services include:
- On-site specialized diagnostic and support services, including hematopathology, molecular diagnosis, immunophenotyping, special cell component therapy and pheresis, and infectious disease specialists
- Integrated programs with the Blood and Marrow Transplant Program
- Second opinions
- New therapies
We also treat benign hematology – bleeding disorders, red cell disorders, platelet abnormalities and white cell disorders.
A major goal of Hematologic Malignancies Service is to develop new curative approaches for leukemias, lymphomas and myelomas. For example:
- We offer a number of NCI-funded Phase I and II innovative clinical trials of new drugs and novel drug combinations for patients with newly diagnosed or relapsed and/or refractory leukemias and myelodysplasia.
- We use novel immunotherapy approaches to treat Chronic Myelogenous Leukemia (CML), lymphoma and multiple myeloma.
- We offer new molecularly-targeted drugs for multiple myeloma.
